BR Biopharma, Inc. (NASDAQ:BRBI - Get Free Report) traded up 0.2% during mid-day trading on Tuesday . The stock traded as high as $16.39 and last traded at $16.39. 1,224 shares changed hands during trading, a decline of 73% from the average session volume of 4,502 shares. The stock had previously closed at $16.35.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings started coverage on shares of BR Biopharma in a research report on Friday, February 13th. They set a "sell (e-)" rating on the stock. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, BR Biopharma has an average rating of "Sell".
View Our Latest Stock Report on BRBI
BR Biopharma Trading Up 0.2%
The firm has a 50-day moving average of $14.79.
BR Biopharma (NASDAQ:BRBI - Get Free Report) last announced its quarterly earnings data on Tuesday, February 3rd. The company reported $0.16 earnings per share for the quarter. The business had revenue of $23.81 million during the quarter.
About BR Biopharma
(
Get Free Report)
BRBI BR Partners SA, through its subsidiaries, operates as an investment bank which specializes in providing financial services for entrepreneurs and families principally in Brazil. It offers financial advisory services for mergers and acquisitions, capital markets, board services, shareholders, special situations and restructuring, pre-IPO, and privatization; and wealth management services. BRBI BR Partners SA is based in S?o Paulo, Brazil.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider BR Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BR Biopharma wasn't on the list.
While BR Biopharma currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
